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Abstract 
HIV increases the likelihood that a person will develop TB. Starting them on anti-retroviral therapy (ART) reduces their risk of 
TB but not to the level in HIV negative people. Since HIV-positive people who are on ART can expect to live a normal life for 
several decades this raises the possibility that their elevated risk of infection, lasting for a long time, could lead to an increase 
in the population level incidence of TB. Here we investigate the conditions under which this could happen and show that 
provided HIV-positive people start ART when their CD4+ cell count is greater than 350/µL and that there is high coverage, 
ART will not lead to a long-term increase in HIV. Only if people start ART very late and there is low coverage of ART might 
starting people on ART increase the population level incidence of TB. 
 
Introduction 
Detailed epidemiological models have shown that TasP, or 
‘treatment-as-prevention’, can eliminate HIV1 and HIV-
related TB.2 When people are infected with HIV their risk 
of developing TB increases exponentially with declining 
CD4+ T-lymphocyte cell counts (hereafter ‘CD4 count’).3 
When such people are on anti-retroviral therapy (ART) 
their CD4 counts recover over a period of four to five 
years4-6 and the risk of developing TB falls by about 60% at 
all CD4 counts.2 Nevertheless, because the incidence of TB 
in HIV-positive people on ART remains higher than it is in 
HIV-negative people and people on ART should live for a 
long time, the possibility exists that under some 
circumstances ART could have the paradoxical effect of 
increasing the overall incidence of TB. Here we explore the 
conditions under which this might happen. 
Methods and assumptions 
We assume:  
1. That the median CD4 count in HIV negative people is 
1,200/µL; observed values range widely6,7 from 
1,150/µL8 in a study in Uganda to 591/µL in a study in 
Botswana;9 
2. That the CD4 count drops by 25% immediately after the 
acute phase of infection,7 that is about one month after 
infection with HIV;10  
3. That after the acute phase of infection the CD4 counts 
falls linearly to zero,7 when the person dies if they do not 
receive ART; 
4. That the median life expectancy for HIV positive people, 
without ART, is ten years6,11 and with ART is forty 
years;12 
5. The incidence of TB in HIV-positive people increases by 
38% (25%!53%) for each decrease of 100 cells per µL3 
as the HIV-infection progresses, based on studies in 
Italy13 and in Cape Town (Figure 1);14  
6. When people start ART their CD4 count converges 
exponentially with time to an asymptote that is 371/µL 
(362/µL!381/µL) above the value at which they start 
ART at a rate of 0.60 (0.55!0.66) per year.4,6 This 
increase in CD4 counts implies a reduction in TB 
incidence of 76% (60%!85%).* Direct estimates of TB 
                                                            
*  Risk reduction = 1! e!371"0.0038 
comparing people on and off ART suggest a reduction of 
61% (54%!68%).2 
 We consider a person infected with HIV, calculate the 
relative risk of developing TB as their CD4 counts decline 
with time since infection and then as their CD4 counts 
increase once they are on ART. We assume that people 
who start ART, are fully adherent with treatment, and have 
good viral load suppression will live for 40 years.12 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. TB incidence as a function of CD4 
counts in HIV-positive people from studies in 
public hospitals in Italy13 and South Africa.14 The 
fitted lines have a slope of 0.0038 
(0.0025!0.0053) µL.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The decline and recovery of the CD4+ T-cell 
count after infection with ART assuming that people start 
treatment at different CD4 counts. The lines, from the 
bottom (red) to the top (brown), correspond to starting 
CD4 counts of 0, 100, 200, … 700/µL. 
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Results 
The decline and the recovery of CD4 counts is shown in 
Figure 2 and the incidence of TB is shown in Figure 3, in 
both cases as a function of the time since infection with 
HIV and the CD4 count at which people start ART. From 
the data in Figure 3 we calculate the lifetime risk of TB as a 
function of the CD4 counts at the start of treatment (Figure 
4); the red dots and lines are for a person who never starts 
ART and dies after ten years. The intersection of the red 
line with the horizontal axis gives the value of the CD4 
count at which the lifetime risk of developing TB is the 
same with and without ART. This CD4 count defines a 
threshold above which ART reduces the lifetime risk of TB 
and below which it increases the lifetime risk of TB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The relative risk of TB as a function of the CD4 
count at the start of treatment and the time since infection. 
The reference value of 1 corresponds to the incidence of 
TB in HIV-negative people for the same population. The 
lines from the top (red) to the bottom (brown) correspond 
to starting ART at CD4 counts of 0, 100, 200, … 700/µL. 
The incidence of TB increases at a rate of 38% for each 
drop of 100 cells/µL in the CD4 count. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The lifetime risk of TB as a function of the CD4 
count at the start of treatment. The red dots and line are for 
a person who never starts treatment and dies ten years 
after they are infected. 
 If a person has a CD4 count of 1,200/µL, never starts 
ART and dies after ten years, and the risk of TB increases 
at 38%/µL, their lifetime risk of developing TB is 24% 
(black line, Figure 3; red dots, Figure 3Figure 4). Provided 
they start ART at a CD4 count greater than 335/µL their 
lifetime risk of TB is less than if they never started 
treatment and vice versa (Figure 4). 
 The two key parameters in the model are the CD4 
count, before the person becomes infected with HIV, and 
the rate of increase in the incidence of TB as the CD4 count 
declines. To investigate the sensitivity of the CD4 threshold 
to these parameters we vary the mean CD4 count in HIV-
negative people from 600/µL to 1,200/µL. Reducing the 
initial CD4 count reduces the both the lifetime risk at any 
CD4 count, the life-time risk without treatment, and the 
critical value of the CD4 count, below which treatment 
increases the life-time risk of TB. Because they all vary in a 
similar way the CD4 threshold only varies from 338/µL to 
371/µL as shown in Figure 5. 
 Survival without ART is sensitive to age and can be as 
long as 16 years for those infected at age 4 years to 4 years 
for those infected at age 65 years.15 However, the CD4 
threshold is also insensitive to changing the life expectancy 
from ten years to five or fifteen years. Doubling the life 
expectancy, say, reduces the rate at which CD4 counts 
decline by one-half, which is equivalent to halving the 
initial CD4 count, and this does not change the threshold 
CD4 significantly. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The CD4 threshold, below which ART will lead 
to an increase in the incidence of TB, as a function of the 
CD4 counts in HIV-negative people. 
 However, changing the rate at which the incidence of 
TB increases as the CD4 count falls has a much greater 
effect on the CD4 threshold. If we set the CD4 count in 
HIV-negative people to 900/µL, and set the rate parameter 
to the lower limit of 0.0025 µL/cell, the lifetime risk of TB 
without treatment falls to 8% and CD4 threshold increases 
to 560/µL. Setting the rate parameter to the upper limit of 
0.0053 µL/cell the lifetime risk of TB without treatment 
increases to 72% and CD4 threshold falls to 206/µL.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The CD4 threshold, below which ART will lead 
to an increase in the incidence of TB, as a function of the 
rate of increase of TB with declining CD4 counts, 
Discussion 
We have only considered average values for the initial CD4 
counts and for survival even though both vary widely. 
Since the results are insensitive to the initial CD4 count or 
µ 
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to the survival without ART, this is unlikely to affect the 
conclusions. The only substantial uncertainty arises from 
the estimate of the rate at which the incidence of TB 
increases with declining CD4 counts and better data on this 
would be informative. 
 In this analysis we assume that the CD4 count declines 
linearly with time. While this does have some support16-19 it 
needs further verification. 
 The assumption that the extent of the recovery of CD4 
counts after the start of ART is independent of the CD4 
count at which people start treatment is curious but has 
strong support from two studies.4-6 Given the variation in 
the CD4 counts in HIV-negative people7 it would be useful 
to have similar data for other populations. 
Conclusion 
Increasing the CD4 count at which people start treatment 
will always reduce a person’s lifetime risk of developing 
TB. To ensure that this risk is also less than the risk in 
people who never start ART, and die ten years after they 
become infected with HIV, HIV-positive people should 
start ART at a threshold CD4 count above about 350 
cells/µL. This threshold is insensitive to their CD4 count 
before they become in infected with HIV but is sensitive to 
the rate at which the incidence of TB increases as CD4 
counts fall. This analysis also ignores the substantial 
reduction in HIV prevalence, and therefore of HIV-related 
TB,2 that would result from widespread use of ART and it 
is unlikely that the wide spread use of ART will increase 
the overall incidence of TB. 
Conclusion 
If people start ART very late in the course of their infection 
this will increase their lifetime risk of TB. Since it will also 
have little impact on the overall prevalence of untreated 
HIV it will lead to a long-term increase in the incidence of 
TB in the population as a whole. If people start ART very 
early in the course of their infection this will decrease their 
lifetime risk of TB. If coverage of ART is also high this 
will have a substantial impact on the overall prevalence of 
untreated HIV and lead to a long-term decrease in the 
incidence of TB in the population as a whole. 
 Our best estimate of the CD4 threshold, which 
determines whether ART increases or decreases TB 
incidence in the long term, is about 350 cells/µL. If ART is 
started at this value of the CD4 count the lifetime risk of 
TB is about the same as in people who never start ART. 
However, provide there is high coverage, starting ART at 
this threshold ART should reduce the overall incidence of 
HIV by about 50% and the steady state prevalence of HIV 
by about 30%,2 which will ensure that the overall incidence 
of TB falls. 
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